11-9979-42

antibody from Invitrogen Antibodies

Targeting: PTPRC CD45, GP180, LCA, T200

Provider product page for 11-9979-42

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [8]
Comments [0]
Validations
Flow cytometry [2]
Other assay [1]

Submit

Product number: 11-9979-42 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD45RA Monoclonal Antibody (JS-83), FITC, eBioscience™
Antibody type: Monoclonal
Antigen: Other
Description: Description: The JS-83 monoclonal antibody reacts with human CD45RA, a 220 kDa molecule expressed by subpopulations of CD4^+ peripheral T lymphocytes, CD8^+ peripheral T lymphocytes, and B cells. The CD45RA^+ T cell populations are mainly naive/virgin allowing the use of JS-83 mAb as a phenotypic marker to discriminate T cell subsets.
Conjugate: Green dye
Antibody clone number: JS-83
Concentration: 5 µL/Test

PTPRC protein structure - 11-9979-42 shown in red.

Submitted references IL-32γ potentiates tumor immunity in melanoma.

Gruber T, Kremenovic M, Sadozai H, Rombini N, Baeriswyl L, Maibach F, Modlin RL, Gilliet M, von Werdt D, Hunger RE, Seyed Jafari SM, Parisi G, Abril-Rodriguez G, Ribas A, Schenk M
JCI insight 2020 Sep 17;5(18)

Functionally specialized human CD4(+) T-cell subsets express physicochemically distinct TCRs.

Kasatskaya SA, Ladell K, Egorov ES, Miners KL, Davydov AN, Metsger M, Staroverov DB, Matveyshina EK, Shagina IA, Mamedov IZ, Izraelson M, Shelyakin PV, Britanova OV, Price DA, Chudakov DM
eLife 2020 Dec 8;9

The Changing Landscape of Naive T Cell Receptor Repertoire With Human Aging.

Egorov ES, Kasatskaya SA, Zubov VN, Izraelson M, Nakonechnaya TO, Staroverov DB, Angius A, Cucca F, Mamedov IZ, Rosati E, Franke A, Shugay M, Pogorelyy MV, Chudakov DM, Britanova OV
Frontiers in immunology 2018;9:1618

B cells from African American lupus patients exhibit an activated phenotype.

Menard LC, Habte S, Gonsiorek W, Lee D, Banas D, Holloway DA, Manjarrez-Orduno N, Cunningham M, Stetsko D, Casano F, Kansal S, Davis PM, Carman J, Zhang CK, Abidi F, Furie R, Nadler SG, Suchard SJ
JCI insight 2016 Jun 16;1(9):e87310

Protective genotypes in HIV infection reflect superior function of KIR3DS1+ over KIR3DL1+ CD8+ T cells.

Zipperlen K, Gallant M, Stapleton S, Heath J, Barrett L, Grant M
Immunology and cell biology 2015 Jan;93(1):67-76

Britanova OV, Putintseva EV, Shugay M, Merzlyak EM, Turchaninova MA, Staroverov DB, Bolotin DA, Lukyanov S, Bogdanova EA, Mamedov IZ, Lebedev YB, Chudakov DM
Journal of immunology (Baltimore, Md. : 1950) 2014 Mar 15;192(6):2689-98

Mother and child T cell receptor repertoires: deep profiling study.

Putintseva EV, Britanova OV, Staroverov DB, Merzlyak EM, Turchaninova MA, Shugay M, Bolotin DA, Pogorelyy MV, Mamedov IZ, Bobrynina V, Maschan M, Lebedev YB, Chudakov DM
Frontiers in immunology 2013;4:463

Divergent adaptive and innate immunological responses are observed in humans following blunt trauma.

Kasten KR, Goetzman HS, Reid MR, Rasper AM, Adediran SG, Robinson CT, Cave CM, Solomkin JS, Lentsch AB, Johannigman JA, Caldwell CC
BMC immunology 2010 Jan 25;11:4

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Normal human peripheral blood cells were stained with Mouse IgG1 K Isotype Control FITC (Product # 11-4714-42) (open histogram) or Anti-Human CD45RA FITC (filled histogram). Cells in the lymphocyte population were used for analysis.
Conjugate: Green dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Normal human peripheral blood cells were stained with Mouse IgG1 kappa Isotype Control, FITC (Product # 11-4714-42) (blue histogram) or CD45RA Monoclonal Antibody, FITC (purple histogram). Cells in the lymphocyte gate were used for analysis.
Conjugate: Green dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 IL-32 induces a systemic CD8 + T cell-mediated tumor-specific immune response. ( A ) Experimental setup for in vivo tumor treatments. MC38 and B16F10 were inoculated in C57BL/6J mice, and 4T1 tumors in BALB/c mice ( A - O ). ( B ) Growth curves of IL-32-, cGAMP-, or PBS-treated primary and ( C ) contralateral, nontreated B16F10 melanomas. * P < 0.05, ** P < 0.01, *** P < 0.001. Data are representative of 4 independent experiments, with n = 6 mice per group. ( D ) Kaplan-Meier survival curves of B16F10-bearing mice treated with IL-32 ( n = 6) or PBS ( n = 8). ( E ) Representative growth curves of IL-32-treated and untreated MC38 colon adenocarcinoma ( n = 6) and ( F ) orthotopic 4T1 breast tumors ( n = 10). ( G-O ) On day 14, the primary treated tumors and spleens were harvested for flow cytometric analyses, IHC or TCRbeta chain sequencing. ( G ) Representative flow cytometry plots displaying frequencies of CD45 + immune cells for each treatment group and ( H ) their quantification shown as relative frequencies ( n = 18). ( I ) Relative frequencies of CD8 + and CD4 + T cells as a percentage of live cells ( n = 18). ( J ) Representative immunohistochemical staining and ( K ) morphometric enumeration as cells/mm 2 of CD8 + T cells ( n = 3). Scale bar: 20 mum. ( L ) Relative frequencies of IFN-gamma + cells as percentage of CD8 + T cells ( n = 12). ( M ) Frequencies of Nur77-GFP + cells of CD8 + T cells, as determined by flow cytometry in B16F10-inoculated and PBS- ( n =
Conjugate: Green dye